

# Using Joint Models to Estimate Causal Effects for Salvage Therapy after Prostatectomy

Dimitris Rizopoulos<sup>1</sup>, Jeremy M.G. Taylor<sup>2</sup> and Grigorios Papageorgiou<sup>1</sup>

<sup>1</sup>Department of Biostatistics, Erasmus Medical Center Rotterdam

<sup>2</sup>Department of Biostatistics, University of Michigan



d.rizopoulos@erasmusmc.nl



@drizopoulos

## Contents

<b>Aims, Models &amp; Estimands</b>	<b>3</b>
1 Background & Aim . . . . .	4
2 Causal ST Effects . . . . .	14
3 Structural Models . . . . .	21
4 PSA Sub-Model . . . . .	24
5 Metastasis and Death Sub-Models . . . . .	28
6 Causal Effect Estimation . . . . .	37
7 Results . . . . .	41
8 Extensions & Discussion . . . . .	45

# Aims, Models & Estimands

# 1 Background & Aim

---

- **Setting** Patients treated with surgery after diagnosis of Prostate Cancer (PCa)
  - ▷ *remain at risk of metastasis*
  
- Follow-up
  - ▷ PSA levels at frequent intervals
  - ▷ when PSA increases, physicians consider Salvage Therapy (ST)
  - ▷ ST androgen deprivation therapy, radiation therapy, chemotherapy, and combinations

# 1 Background & Aim (cont'd)

---

- Important questions regarding Salvage Therapy
  - ▷ *who should take it?*
  - ▷ *when to start?*
  - ▷ *does it work?*

# 1 Background & Aim (cont'd)

---

**Quantify the amount by which Salvage Therapy  
reduces the risk of metastasis**


# 1 Background & Aim (cont'd)

---

- **University of Michigan Prostatectomy Data**


- ▷ 3672 PCa patients treated with prostatectomy 1994–2013
- ▷ baseline variables: PSA, Gleason, T-stage, age, race, gland volume, perineural invasion, planned adjuvant therapy
- ▷ follow-up variables:
  - \* post-surgery PSA values (median = 6)
  - \* post-surgery salvage therapy ( $n = 324$ )
  - \* PSA values also after salvage (median = 3)
  
  - \* metastasis ( $n = 108$ )
  - \* death information ( $n = 212$ )

# 1 Background & Aim (cont'd)







# 1 Background & Aim (cont'd)




# 1 Background & Aim (cont'd)



# 1 Background & Aim (cont'd)



# 1 Background & Aim (cont'd)



# 1 Background & Aim (cont'd)

---

- **Challenges**

- ▷ *Observational Data – no RCT*

- \* selection bias
- \* ascertainment bias

- ▷ *Time-Varying Salvage Therapy*

- \* depends on previous PSA
- \* PSA time-dependent confounder
- \* endogeneity

## 2 Causal ST Effects

---


- Standard assumptions for Causal Inference
  - ▷ *Consistency*: Observed outcomes equal the counterfactual outcomes for the actually assigned treatment
  - ▷ *Sequential Exchangeability*: The counterfactual outcomes are independent of the assigned treatment conditionally on the history of PSA measurements and baseline covariates
  - ▷ *Positivity*: Each patient has a nonzero probability of receiving ST at each time point  $t$

## 2 Causal ST Effects (cont'd)

---

- Setting
  - ▷ PSA measurements up to  $t$
  - ▷ no Salvage Therapy given up to  $t$
  - ▷ we compare cumulative risk of metastasis in the medically-relevant interval  $[t, t + \Delta t]$
  - ▷ under the two regimes
    1. if Salvage Therapy is **not** given in the interval  $[t, t + \Delta t]$
    2. if Salvage Therapy is given at  $t$

## 2 Causal ST Effects (cont'd)





## 2 Causal ST Effects (cont'd)

---

**Which is the target group?**

- Notation

- ▷  $T_m$ : time to metastasis
- ▷  $T_d$ : time to death
- ▷  $\mathcal{H}^*(t)$ : a version of the PSA history up to  $t$
  
- ▷  $T_m^{(a)}$  and  $T_d^{(a)}$  counterfactual outcomes
  - \*  $a = 1$ , ST given at  $t$
  - \*  $a = 0$ , ST was not given in  $[t, t + \Delta t]$

## 2 Causal ST Effects (cont'd)

---

- **Marginal Salvage Therapy Effect**

▷ we average over all PSA histories, i.e.,  $\mathcal{H}^*(t) = \emptyset$

$$ST^M(t + \Delta t, t) = \Pr\{T_m^{(1)} \leq t + \Delta t \mid T_m > t, T_d > t\} - \Pr\{T_m^{(0)} \leq t + \Delta t \mid T_m > t, T_d > t\}$$

- **Notes:**

▷ of lesser relevance to the urologists because they decide who gets ST based on PSA  $\Rightarrow$  **more bias**

▷ averages over a big groups of patients  $\Rightarrow$  **less variance**

## 2 Causal ST Effects (cont'd)

---

- **Conditional Salvage Therapy Effect**

▷ we condition on the PSA history of a specific patient, i.e.,  $\mathcal{H}^*(t) = \mathcal{H}_i(t)$

$$\begin{aligned} \text{ST}^C(t + \Delta t, t) &= \Pr\{T_m^{(1)} \leq t + \Delta t \mid T_m > t, T_d > t, \mathcal{H}_i(t)\} \\ &\quad - \Pr\{T_m^{(0)} \leq t + \Delta t \mid T_m > t, T_d > t, \mathcal{H}_i(t)\} \end{aligned}$$

- **Notes:**

▷ much more relevant to the urologists  $\Rightarrow$  **less bias**

▷ averages over a narrow group of patients identified via modeling assumptions  $\Rightarrow$  **more variance**

## 2 Causal ST Effects (cont'd)

---

- Marginal-Conditional Salvage Therapy Effect

▷ consider ST for patients who had PSA levels above the threshold value  $c$  at their last visit, i.e.,  $\mathcal{H}^*(t) = \{Y(t) : Y(t) > c\}$

$$\begin{aligned} \text{ST}^{MC}(t + \Delta t, t) = & \Pr\{T_m^{(1)} \leq t + \Delta t \mid T_m > t, T_d > t, \mathcal{H}^*(t)\} \\ & - \Pr\{T_m^{(0)} \leq t + \Delta t \mid T_m > t, T_d > t, \mathcal{H}^*(t)\} \end{aligned}$$

- Notes:

▷ relevant to the urologists  $\Rightarrow$  **compromised bias**

▷ averages over a bigger group of patients  $\Rightarrow$  **compromised variance**

# 3 Structural Models


---

Standard Cox models not appropriate



**Joint Models for Longitudinal and  
Time-to-Event Data**

### 3 Structural Models (cont'd)



### 3 Structural Models (cont'd)

---

**Joint models completely specify the joint distribution of PSA, time-to-metastasis & time-to-death**

- Under sequential ignorability,
  - ▷ they provide valid marginal distributions
  - ▷ *without requiring* to model the treatment assignment mechanism

## 4 PSA Sub-Model

---

- As PSA increases, patient may receive ST
- We let  $S_i$  denote the time a patient initiated ST
  - ▷ for patients who did not initiate ST,  $S_i = \infty$
- After ST, PSA levels are expected to drop
  - ▷ but may rise again before metastasis




## 4 PSA Sub-Model (cont'd)

---

$$\log\{\text{PSA}_i(t) + 1\} = \begin{cases} \eta_i(t) + \varepsilon_i(t) = \mathbf{x}_i(t)\boldsymbol{\beta} + \mathbf{z}_i(t)\mathbf{b}_i + \varepsilon_i(t), & t < S_i \\ \tilde{\eta}_i(t) + \varepsilon_i(t) = \\ \eta_i(t) + \left\{ \tilde{\mathbf{x}}_i(\tilde{t})\tilde{\boldsymbol{\beta}} + \tilde{\mathbf{z}}_i(t)\tilde{\mathbf{b}}_i \right\} + \varepsilon_i(t), & t \geq S_i, \end{cases}$$


## 4 PSA Sub-Model (cont'd)

---




## 4 PSA Sub-Model (cont'd)

---




## 4 PSA Sub-Model (cont'd)


---




## 4 PSA Sub-Model (cont'd)




## 4 PSA Sub-Model (cont'd)



## 4 PSA Sub-Model (cont'd)




## 4 PSA Sub-Model (cont'd)







## 4 PSA Sub-Model (cont'd)



## 4 PSA Sub-Model (cont'd)



## 4 PSA Sub-Model (cont'd)



## 4 PSA Sub-Model (cont'd)

---

### The model used in the UM data

- Fixed effects
  - ▷ *Before Salvage*: Nonlinear PSA evolution (B-spline with 6 internal knots)
  - ▷ *After Salvage*: Drop in PSA, and linear evolution
  - ▷ baseline covariates: Age, baseline PSA, Gleason score, Charlson comorbidity index, perineural invasion
- Random effects
  - ▷ *the same time effect as in the fixed part*

## 5 Metastasis and Death Sub-Models

---

- Metastasis and Death treated as *Competing Risks*
- Separate hazard models for metastasis and death
  - ▷ linked with PSA and ST
  - ▷ baseline covariates

## 5 Metastasis and Death Sub-Models (cont'd)

---

- **Metastasis Sub-Model** linked to baseline covariates, Salvage and PSA

$$h_i^m(t) = \begin{cases} h_0^m(t) \exp\left(\boldsymbol{\psi}_m^\top \mathbf{w}_i + \boldsymbol{\alpha}_m^\top f\{\eta_i(t)\}\right), & t < S_i \\ h_0^m(t) \exp\left(\boldsymbol{\psi}_m^\top \mathbf{w}_i + \gamma_m(t - S_i) + \boldsymbol{\xi}_m^\top g\{\tilde{\eta}_i(t)\}\right), & t \geq S_i \end{cases}$$

## 5 Metastasis and Death (cont'd)

---

- Functions  $f(\cdot)$  and  $g(\cdot)$  specify the functional form
  - ▷ how PSA *before* and *after* Salvage is linked to metastasis
  
- Some options are...

## 5 Metastasis and Death (cont'd)

---

- *Time-dependent Slopes*: The hazard of metastasis at  $t$  is associated with both the current value and the slope of the PSA trajectory at  $t$ :


$$h_i^m(t | \mathcal{H}_i(t)) = h_0^m(t) \exp\{\boldsymbol{\psi}_m^\top \boldsymbol{w}_i + \alpha_{m1}\eta_i(t) + \alpha_{m2}\eta_i'(t)\},$$

where

$$\eta_i'(t) = \frac{d}{dt}\{x_i^\top(t)\boldsymbol{\beta} + z_i^\top(t)\boldsymbol{b}_i\}$$



# 5 Metastasis and Death (cont'd)



## 5 Metastasis and Death (cont'd)


---

- *Cumulative Effects*: The hazard of metastasis at  $t$  is associated with the whole area under the trajectory up to  $t$ :

$$h_i(t \mid \mathcal{M}_i(t)) = h_0(t) \exp \left\{ \gamma^\top w_i + \alpha \frac{\int_0^t m_i(s) ds}{t} \right\}$$

We account for the observation period

# 5 Metastasis and Death (cont'd)



# 5 Metastasis and Death (cont'd)

---

## Models used in the UM data

- Functional forms
  - ▷ *Before Salvage*: Nonlinear PSA evolution (B-spline with 6 internal knots)
    - \* value
    - \* value + slope
    - \* value + cumulative effect
  - ▷ *After Salvage*: Drop in PSA, and linear evolution
    - \* drop in PSA
    - \* slope
  - ▷ baseline covariates: Age, baseline PSA, Gleason score, Charlson, perineural inv.

## 5 Metastasis and Death (cont'd)

---

- **Death Sub-Model** linked to baseline covariates, Salvage and *but not* PSA

$$h_i^d(t) = \begin{cases} h_0^d(t) \exp(\boldsymbol{\psi}_d^\top \mathbf{w}_i), & t < S_i \\ h_0^d(t) \exp(\boldsymbol{\psi}_d^\top \mathbf{w}_i + \gamma_d), & t \geq S_i \end{cases}$$

## 6 Causal Effect Estimation

---

- From the joint model, we can obtain the conditional causal effect

$$\Pr\{T_{mi}^{(a)} \leq t + \Delta t \mid T_{mi} > t, T_{di} > t, \mathcal{H}_i(t), \mathcal{X}_i\} =$$

$$\int \int \Pr\{T_{mi}^{(a)} \leq t + \Delta t \mid T_{mi} > t, T_{di} > t, \mathbf{u}_i, \mathcal{X}_i, \boldsymbol{\theta}\}$$

$$\times p\{\mathbf{u}_i \mid T_{mi} > t, T_{di} > t, \mathcal{H}_i(t), \mathcal{X}_i, \boldsymbol{\theta}\} p(\boldsymbol{\theta} \mid \mathcal{D}) d\mathbf{u}_i d\boldsymbol{\theta}$$

▷  $a = \{0, 1\}$

▷  $\mathcal{D} = \{T_i, \delta_i, Y_i; i = 1, \dots, n\}$

▷  $p(\boldsymbol{\theta} \mid \mathcal{D})$  posterior

## 6 Causal Effect Estimation (cont'd)

---

- Monte Carlo scheme to estimate  $ST_i^C(t + \Delta t, t)$ 
  - ▷ sample  $\check{\boldsymbol{\theta}}^{(l)}$  from the posterior of the parameters  $[\boldsymbol{\theta} \mid \mathcal{D}]$
  - ▷ sample  $\check{\mathbf{u}}_i^{(l)}$  from the posterior of the random effects  $[\mathbf{u}_i \mid T_{mi} > t, T_{di} > t, \mathcal{H}_i(t), \mathcal{X}_i, \check{\boldsymbol{\theta}}^{(l)}]$
  - ▷ calculate  $\pi_i^{(l)}(t + \Delta t \mid t, a) = \Pr\{T_{mi}^{(a)} \leq t + \Delta t \mid T_{mi} > t, T_{di} > t, \check{\mathbf{u}}_i^{(l)}, \mathcal{X}_i, \check{\boldsymbol{\theta}}^{(l)}\}$
  
- We repeat  $L$  times and get

$$\widehat{ST}_i^C(t + \Delta t, t) = \frac{1}{L} \sum_{l=1}^L \pi_i^{(l)}(t + \Delta t \mid t, a = 1) - \pi_i^{(l)}(t + \Delta t \mid t, a = 0)$$

## 6 Causal Effect Estimation (cont'd)

---

- Estimation of  $ST^M(t + \Delta t, t)$  and  $ST^{MC}(t + \Delta t, t)$  proceeds by averaging the conditional effects over the respective groups of patients
- For example, for  $ST^M(t + \Delta t, t)$ 
  - ▷  $\mathcal{R}(t)$  the subset of patients at risk at time  $t$  and who have not initiated ST by  $t$
  - ▷ for each patient in  $\mathcal{R}(t)$ , we calculate  $\widehat{ST}_i^C(t + \Delta t, t)$

$$\widehat{ST}^M(t + \Delta t, t) = n_r^{-1} \sum_{i:i \in R(t)} \widehat{ST}_i^C(t + \Delta t, t),$$



## 6 Causal Effect Estimation (cont'd)


---

- To estimate the variance of the causal effects, we need to take into account that they are a function of both the parameters  $\theta$  and the data  $\mathcal{D}$


$$\text{Var}_{\mathcal{D}}\{\widehat{ST}^M(t + \Delta t, t; \theta, \mathcal{D})\} = \text{Var}_{\mathcal{D}}\left[E_{\theta|\mathcal{D}}\left\{ST^M(t + \Delta t, t; \theta, \mathcal{D})\right\}\right]$$

- We achieve this using an adaptation of the procedure of Antonelli et al. (2021)


# 7 Results




# 7 Results (cont'd)



# 7 Results (cont'd)



# 7 Results (cont'd)




## 8 Extensions & Discussion

---

- *Competing Risks*  $\Rightarrow$  *Multi-State*
- *Competing Risks*
  - ▷ metastasis or death, whatever comes first
  - ▷ salvage as a time-varying covariate
- *Multi-State*
  - ▷ salvage as an extra state
  - ▷ metastasis  $\rightarrow$  death transition

## 8 Extensions & Discussion (cont'd)



## 8 Extensions & Discussion (cont'd)

---

- Implementation available in **JMbayes2**
  - ▷ `predict()` cumulative incidence risks
  - ▷ `causal_effects()` calculates the different causal effects (not yet in the package, but in GitHub)
  
- Shiny app...



**Thank for your attention!**

<https://www.drizopoulos.com/>

## 8 Causal Effect Estimation (cont'd)

- Where the first term is written as

$$\Pr\{T_{mi}^{(a)} \leq t + \Delta t, | T_{mi} > t, T_{di} > t, \mathbf{u}_i, \mathcal{X}_i, \boldsymbol{\theta}\} =$$
$$\frac{\int_t^{t+\Delta t} h_i^{m(a)}(v) \exp\left(-\int_t^v \{h_i^{m(a)}(s) + h_i^{d(a)}(s)\} ds - \int_0^t \{h_i^{m(0)}(s) + h_i^{d(0)}(s)\} ds\right) dv}{\exp\left(-\int_0^t \{h_i^{m(0)}(s) + h_i^{d(0)}(s)\} ds\right)}$$

## 8 Causal Effect Estimation (cont'd)

- Using telescoping we get:

$$\begin{aligned} & p(\boldsymbol{\theta}, \mathbf{u}, \boldsymbol{\theta}_N \mid T, \delta, \mathbf{Y}, \mathbf{N}) \\ & \propto \prod_{i=1}^n \prod_{j=1}^{n_i} p\{Y_i(t_{ij}), T_i, \delta_i \mid \mathcal{Y}_i(t_{i,j-1}), \mathcal{N}_i(t_{i,j-1}), \mathcal{X}_i, \boldsymbol{\theta}, \mathbf{u}_i\} \\ & \quad \times \prod_{j=1}^{n_i} p\{N_i(t_{ij}) \mid \mathcal{Y}_i(t_{i,j-1}), \mathcal{N}_i(t_{i,j-1}), Y_i(t_{ij}), T_i, \delta_i, \mathcal{X}_i, \boldsymbol{\theta}_N, \mathbf{u}_i\} \\ & \quad \times p(\mathbf{u}_i \mid \boldsymbol{\theta}) \times p(\boldsymbol{\theta}) \times p(\boldsymbol{\theta}_N) \end{aligned}$$

## 8 Causal Effect Estimation (cont'd)

---

- Under sequential exchangeability, we have that

$$p\{N_i(t_{ij}) \mid \mathcal{Y}_i(t_{i,j-1}), \mathcal{N}_i(t_{i,j-1}), Y_i(t_{ij}), T_i, \delta_i, \mathcal{X}_i, \boldsymbol{\theta}_N, \mathbf{u}_i\} = \\ p\{N_i(t_{ij}) \mid \mathcal{Y}_i(t_{i,j-1}), \mathcal{N}_i(t_{i,j-1}), \mathcal{X}_i, \boldsymbol{\theta}_N\}$$

- $\Rightarrow$  inference can be based on the first term (i.e., the observed data model) and ignore the second term

## 8 Computational Details (cont'd)

---

- Custom-made and tailored MCMC algorithm
  - ▷ Gibbs sampling (hierarchical centering for fixed effects)
  - ▷ adaptive Metropolis-Hastings
  - ▷ (Metropolis-adjusted Langevin algorithm for certain parameter)
  - ▷ centered design matrices
- Speed via parallel sampling of random effects
- Chains run in parallel

## 8 Results (cont'd)

---

[https://emcbiostatistics.shinyapps.io/Plots\\_PSA/](https://emcbiostatistics.shinyapps.io/Plots_PSA/)